Correction to: Out of the Black Box: Treatment of Resistant Depression in Adolescents and the Antidepressant Controversy by (Journal of Child and Adolescent Psychopharmacology (2012) 22 (5-10) DOI: 10.1089/cap.2011.0045);Out of the black box: Treatment of resistant depression in adolescents and the antidepressant controversy

Journal of Child and Adolescent Psychopharmacology

Volumn 22, Issue 1, 2012, Pages 5-10

  Wagner, Karen Dineen ^a   Asarnow, Joan Rosenbaum ^b   Vitiello, Benedetto ^c   Clarke, Gregory ^d   Keller, Martin ^e   Emslie, Graham J ^f   Ryan, Neal ^g   Porta, Giovanna ^g   Iyengar, Satish ^h   Ritz, Louise ^c,i   Zelanzny, Jamie ^g   Onorato, Matthew ^j,k   Brent, David ^g  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

^d CENTER FOR HEALTH RESEARCH   (United States)

^e BROWN UNIVERSITY   (United States)

^f UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^g UNIVERSITY OF PITTSBURGH   (United States)

^h UNIVERSITY OF PITTSBURGH   (United States)

ⁱ NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

^j NATIONWIDE CHILDREN S HOSPITAL   (United States)

^k OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDEPRESSANT AGENT; PAROXETINE; SEROTONIN UPTAKE INHIBITOR; VENLAFAXINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL PROTOCOL; COGNITIVE THERAPY; CONTROLLED STUDY; DRUG SUBSTITUTION; DRUG WITHDRAWAL; HUMAN; OUTCOME ASSESSMENT; SUICIDAL BEHAVIOR; TREATMENT RESISTANT DEPRESSION;

EID: 84857300110     PISSN: 10445463     EISSN: 15578992     Source Type: Journal    
DOI: 10.1089/cap.2011.0045.correx     Document Type: Erratum

References (34)

1. Asarnow JR, Emslie G, Clarke G, Wagner KD, Spirito A, Vitiello B, Iyengar S, Shamseddeen W, Ritz L, Mccracken J, Strober M, Suddath R, Leonard H, Porta G, Keller M, Brent D: Treatment of selective serotonin reuptake inhibitor-resistant depression in ado-lescents: Predictors and moderators of treatment response. J Am Acad Child Adolesc Psychiatry 48:330-339, 2009.
2. Brent D, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller M, Vitiello B, Ritz L, Iyengar S, Abebe K, Birmaher B, Ryan N, Kennard B, Hughes C, De Bar L, Mc Cracken J, Strober M, Suddath R, Spirito A, Leonard H, Melhem N, Porta G, Onorato M, Zelazny J: Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: The TORDIA randomized controlled trial. JAMA 299:901-913, 2008. (Pubitemid 351397065)
3. Brent D, Melhem N, Ferrell R, Emslie G, Wagner KD, Ryan N, Vitiello B, Birmaher B, Mayes T, Zelazny J, Onorato M, Devlin B, Clarke G, De Bar L, Keller M: Association of FKBP5 polymor-phisms with suicidal events in the Treatment of Resistant Depres-sion in Adolescents (TORDIA) study. Am J Psychiatry 167: 190-197, 2010.
4. Brent DA, Emslie GJ, Clarke GN, Asarnow J, Spirito A, Ritz L, Vitiello B, Iyengar S, Birmaher B, Ryan ND, Zelazny J, Onorato M, Kennard B, Mayes TL, Debar LL, Mc Cracken JT, Strober M, Suddath R, Leonard H, Porta G, Keller MB: Predictors of sponta-neous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry 166:418-426, 2009.
5. Curtis BM, Barrett BJ, Parfrey PS: The design of randomized con-trolled trials. Methods Mol Biol 473:95-111, 2009.
6. Emslie GJ, Mayes T, Porta G, Vitiello B, Clarke G, Wagner KD, Asarnow JR, Spirito A, Birmaher B, Ryan N, Kennard B, De Bar L, Mc Cracken J, Strober M, Onorato M, Zelazny J, Keller M, Iyengar S, Brent D: Treatment of Resistant Depression in Adolescents (TORDIA): Week 24 outcomes. Am J Psychiatry 167:782-791, 2010.
7. Field MJ, Behrman RE: Ethical Conduct of Clinical Research Invol-ving Children. Washington, DC: The National Academies Press; 2004.
8. Fuhrer MJ: Conducting multiple-site clinical trials in medical reha-bilitation research. Am J Phys Med Rehabil 84:823-831, 2005. (Pubitemid 41546722)
9. Furimsky I, Cheung AH, Dewa CS, Zipursky RB: Strategies to en-hance patient recruitment and retention in research involving pa-tients with a first episode of mental illness. Contemp Clin Trials 29:862-866, 2008.
10. Gold JL, Dewa CS: Institutional review boards and multisite studies in health services research: Is there a better way? Health Serv Res 40:291-307, 2005. (Pubitemid 40229361)
11. Goldstein BI, Shamseddeen W, Spirito A, Emslie G, Clarke G, Wagner KD, Asarnow JR, Vitiello B, Ryan N, Birmaher B, Mayes T, Onorato M, Zelazny J, Brent DA: Substance use and the treat-ment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry 48:1182-1192, 2009.
12. Kennard BD, Clarke GN, Weersing VR, Asarnow JR, Shamseddeen W, Porta G, Berk M, Hughes JL, Spirito A, Emslie GJ, Keller MB, Wagner KD, Brent DA: Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: Preliminary findings. J Consult Clin Psychol 77:1033-1041, 2009.
13. Koelch M, Singer H, Prestel A, Burkert J, Schulze U, Fegert JM: ''.because I am something special'' or ''I think I will be some-thing like a guinea pig'': Information and assent of legal minors in clinical trials\-assessment of understanding, appreciation and rea-soning. Child Adolesc Psychiatry Ment Health 3:2, 2009.
14. Lynch FL, Dickerson JF, Clarke G, Vitiello B, Porta G, Wagner KD, Emslie G, Asarnow JR Jr., Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes T, Debar L, Mc Cracken JT, Strober M, Suddath RL, Spirito A, Onorato M, Zelazny J, Iyengar S, Brent D: Incre-mental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant de-pression: Treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry 68:253-262, 2011.
15. Mc Clure CA, Gray G, Rybczyk GK, Wright PF: Challenges to con-ducting HIV preventative vaccine trials with adolescents. J Acquir Immune Defic Syndr 36:726-733, 2004. (Pubitemid 38685967)
16. Mc Intosh N, Bates P, Brykczynska G, Dunstan G, Goldman A, Har-vey D, Larcher V, Mc Crae D, Mc Kinnon A, Patton M, Saunders J, Shelley P: Guidelines for the ethical conduct of medical research involving children. Royal College of Paediatrics, Child Health: Ethics Advisory Committee. Arch Dis Child 82:177-182, 2000. (Pubitemid 30305718)
17. Medicines and Health Care Products Regulatory Agency: Safety of seroxat (paroxetine) in children and adolescents under 18 years-contraindication in the treatment ofdepressive illness. Message from Professor G Duff, Chairman of the committee on safety ofmedicines. June 10 2003a. www.mhra.gov.uk/home/groups/pl- p/documents/websiteresources/con019507.pdf. Accessed March 17, 2011.
18. Medicines and Health Care Products Regulatory Agency: Safety of velafaxine in children and adolescents under 18 years in the treat-ment of depressive illness. Message from Professor G Duff, Chair-man of the committee on safety ofmedicines. September 19 2003b. www.mhra.gov.uk/home/groups/pl-p/ documents/websiteresources/con019501.pdf. Accessed March 17, 2011.
19. Posner K, Oquendo MA, Stanley B, Davies M, Gould M: Columbia Classification Algorithm of Suicide Assessment (C-CACA): Clas-sification of suicidal events in the FDA's pediatric suicidal risk analysis ofantidepressants. Am J Psychiatry 164:1035-1043, 2007. (Pubitemid 47121392)
20. Sakolsky DJ, Perel JM, Emslie GJ, Clarke GN, Wagner KD, Vitiello B, Keller MB, Birmaher B, Asarnow JR, Ryan ND, Mc Cracken JT, Strober MJ, Iyengar S, Porta G, Brent DA: Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resis-tant Depression in Adolescents (TORDIA) study. J Clin Psycho-pharmacol 31:92-97, 2011.
21. Shamseddeen W, Asarnow JR, Clarke G, Vitiello B, Wagner KD, Birmaher B, Keller MB, Emslie G, Iyengar S, Ryan ND, Mc Cracken JT, Porta G, Mayes T, Brent DA: Impact of physical and sexual abuse on treatment response in the treatment of resistant depression in adolescent study (TORDIA). J Am Acad Child Adolesc Psychiatry 50:293-301, 2011.
22. Tan JO, Koelch M: The ethics of psychopharmacological research in legal minors. Child Adolesc Psychiatry Ment Health 2:39, 2008.
23. U.S. Food and Drug Administration. FDA Public Health Advisory, reports of suicidality in pediatric patients being treated with antidepressant medications for major depressive disorder (MDD). October 27,2003a. www.fda.gov/Drugs/Drug Safety/Postmarket Drug Safety Informationfor Patientsand Providers/Drug Safety Information for Heathcare Professionals/Public Health Advisories/ucm168828.htm. Accessed March 17, 2011.
24. U.S. Food and Drug Administration. FDA Statement regarding the anti-depressant paxil for pediatric population. FDA Talk Paper. June 19, 2003b. www.ahrp.org/infomail/0603/19a.php. Accessed March 17, 2011.
25. U.S. Food and Drug Administration: FDA Public Health Advisory: FDA launches a multi-pronged strategy to strengthen safeguards for children treated with antidepressant medications. October 15, 2004a. www.fda.gov/News Events/Newsroom/Press Announcements/2004/ucm108363.htm. Accessed March 17, 2011.
26. U.S. Food and Drug Administration. FDA Public Health Advisory, worsening depression and suicidality in patients being treated with antidepressant medications. March 22, 2004b. www.fda.gov/Drugs/DrugSafety/Postmarket Drug Safety Informationfor Patientsand Pro viders/Drug Safety Informationfor Heathcare Professionals/Public Health Advisories/ucm161696.htm. Accessed March 17, 2011.
27. U.S. Food and Drug Administration: Public Health Advisory\Combined use of 5-hydroxytryptamine receptor agonists (triptans), selective serotonin reuptake inhibitors (SSRIs) or selective seroto-nin/norepinephrine reuptake inhibitors (SNRIs) may result in life-threatening serotonin syndrome. July 19, 2006a. www.fda.gov/Drugs/Drug Safety/Postmarket Drug Safety Informationfor Patients and Providers/Drug Safety Informationfor Heathcare Professionals/Public Health Advisories/ucm124349.htm. Accessed March 17,2011.
28. U.S. Food and Drug Administration: Public Health Advisory: Treat-ment challenges of depression in pregnancy and the possibility of persistent pulmonary hypertension in newborns. July 19, 2006b. www.fda.gov/Drugs/Drug Safety/Postmarket Drug Safety Information for Patientsand Providers/Drug Safety Informationfor Heathcare Profes-sionals/Public Health Advisories/ucm124348.htm. Accessed March 17, 2011.
29. Vitiello B, Emslie G, Clarke G, Wagner KD, Asarnow JR, Keller MB, Birmaher B, Ryan ND, Kennard B, Mayes TL, Debar L, Lynch F, Dickerson J, Strober M, Suddath R, Mc Cracken JT, Spirito A, Onorato M, Zelazny J, Porta G, Iyengar S, Brent DA: Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: A follow-up study of the TORDIA sample. J Clin Psychiatry 72:388-396, 2011.
30. Wagner KD, Martinez M, Joiner T: Youths' and their parents' atti-tudes and experiences about participation in psychopharmacology treatment research. J Child Adolesc Psychopharmacol 16:298-307, 2006. (Pubitemid 43902426)
31. Woldu H, Porta G, Goldstein T, Sakolsky D, Perel J, Emslie G, Mayes T, Clarke G, Ryan ND, Birmaher B, Wagner KD, Asarnow JR, Keller MB, Brent D: Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry 50:490-498, 2011.
32. Wyeth Pharmaceuticals: Letter to health professionals. August 22, 2003. www.antidepressantsfacts.com/2003-08-22-Wyeth-Effexor-kids.pdf. Accessed March 17, 2011.
33. Wyeth Pharmaceuticals: Letter to health professionals. June 3, 2004. www.fda.gov/downloads/Safety/Med Watch/Safety Information/Safety Alertsfor Human Medical Products/UCM166425.pdf. Accessed March 17, 2011.
34. Wyeth Pharmaceuticals: Letter to health professionals. October 17, 2006. www.fda.gov/downloads/Safety/Med Watch/Safety Information/Safety Alertsfor Human Medical Products/UCM153177.pdf. Accessed March 17, 2011.